Top 25 Start-Up VC Financings, H1 2015
This article was originally published in Start Up
Executive Summary
Venture money has been flowing fast into biotech start-ups, shattering some fundraising records in the first half of this year. We present the top 25 VC deals of H1.
You may also be interested in...
Infectious Disease Companies Catch More Investors
Start-Up surveyed investments into, and exits by, private infectious disease-focused companies from 2013 through the first quarter of 2016, using data from Informa’s Pharma Intelligence's Strategic Transactions and Medtrack databases. Our review reveals an increasing amount of money going into these firms, especially those developing novel antibiotics against drug-resistant bacteria or with novel anti-infective drug development platforms.
Investors Boost Metabolic Companies
Investments in endocrine/metabolic disease-focused medtech companies reached a four-year high in 2015. Biopharma companies grabbed the majority of the funds that have been raised since 2012, and among medtechs, those focused on diabetes fared best.
Mega Medtech M&A Momentum In 2015
Medtech M&A activity has been on the rise for several years along with a surge in the number of higher-valued mega-deals, those worth at least $1 billion. Yet a survey of all deals with known values indicates that median deal value has actually declined.